BDTX

2.12

0.95% 0.02

Handel nachbörslich: 2.14 0.02 +0.94%

Black Diamond Therapeutics Inc (BDTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.10

Offen:

$2.08

24-Stunden-Volumen:

323.61K

Relative Volume:

0.20

Marktkapitalisierung:

$121.80M

Einnahmen:

$70.00M

Nettoeinkommen (Verlust:

$-43.21M

KGV:

-2.7972

EPS:

-0.7579

Netto-Cashflow:

$-34.03M

1W Leistung:

-4.93%

1M Leistung:

+19.10%

6M Leistung:

-13.82%

1J Leistung:

-26.13%

1-Tages-Spanne:

$2.0609

$2.145

1-Wochen-Bereich:

$2.02

$2.225

52-Wochen-Spanne:

$1.60

$4.94

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Firmenname

Black Diamond Therapeutics Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

617-417-5868

Adresse

245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

BDTX's Discussions on Twitter

Compare BDTX vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BDTX Black Diamond Therapeutics Inc	2.12	123.53M	70.00M	-43.21M	-34.03M	-0.7579
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-03	Herabstufung	Guggenheim	Buy → Neutral
2025-11-18	Fortgesetzt	Piper Sandler	Overweight
2025-10-16	Fortgesetzt	Stifel	Buy
2025-09-04	Eingeleitet	Guggenheim	Buy
2025-07-01	Fortgesetzt	Raymond James	Outperform
2024-07-31	Eingeleitet	Raymond James	Outperform
2023-07-14	Eingeleitet	Piper Sandler	Overweight
2023-06-30	Hochstufung	Stifel	Hold → Buy
2023-06-28	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-06-27	Hochstufung	Wedbush	Neutral → Outperform
2022-03-29	Herabstufung	Wedbush	Outperform → Neutral
2022-03-22	Herabstufung	H.C. Wainwright	Buy → Neutral
2021-09-30	Eingeleitet	Stifel	Hold
2021-01-07	Eingeleitet	Wedbush	Outperform
2020-11-24	Eingeleitet	Berenberg	Buy
2020-05-04	Eingeleitet	H.C. Wainwright	Buy
2020-02-24	Eingeleitet	Canaccord Genuity	Buy
2020-02-24	Eingeleitet	Cowen	Outperform
2020-02-24	Eingeleitet	JP Morgan	Overweight
2020-02-24	Eingeleitet	Jefferies	Buy

Alle ansehen

Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten

Aug 20, 2026

Black (BDTX) Q2 2026 Results: EPS Comes in Above Forecast for the Current Session; Latest Reaction: Shares Finish 4.34% Lower in the Available RecordReturn On Assets - vinanet.vn

Aug 20, 2026

Black (BDTX) Move: Moves 4.16% Lower to $2.10 in Latest Trading; Levels: Traders Can Monitor the $1.99-$2.21 Range under the Current SnapshotVolume Rate Change - vinanet.vn

Aug 20, 2026

Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest TradingProfit Growth Outlook - vinanet.vn

Aug 20, 2026

Aug 15, 2026

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Aug 15, 2026

Aug 14, 2026

Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX? - StockInvest.us

Aug 14, 2026

Aug 11, 2026

Black Diamond Settles HMI Cancer-Drug Discovery Patent Lawsuit - news.bloomberglaw.com

Aug 11, 2026

BDTX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 5.56%Mid-Term Outlook - Vinanet

Aug 11, 2026

Aug 10, 2026

Weekly Recap: Silevertinib NSCLC Phase 2 efficacy and $110.5M cash runway - TradingView

Aug 10, 2026

Aug 08, 2026

Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX - MarketBeat

Aug 08, 2026

Aug 07, 2026